Larry D. LyndPhD, BSP
Scientist, Centre for Health Evaluation and Outcome Sciences (CHEOS), Providence Health Care Research Institute; Scientist, Centre for Clinical Epidemiology and Evaluation (C2E2), Vancouver Coastal Health Research Institute
Douglas CM, Wilcox E, Burgess M, Lynd LD. Why orphan drug coverage reimbursement decision-making needs patient and public involvement. Health Policy. 2015 May;119(5):588-96. doi: 10.1016/j.healthpol.2015.01.009. Epub 2015 Jan 19. PMID: 25641123.
Dragojlovic N, Lynd LD. Crowdfunding drug development: the state of play in oncology and rare diseases. Drug Discov Today. 2014 Nov;19(11):1775-1780. doi: 10.1016/j.drudis.2014.06.019. Epub 2014 Jun 25. PMID: 24973645.
Ungar WJ, Hadioonzadeh A, Najafzadeh M, Tsao NW, Dell S, Lynd LD. Quantifying preferences for asthma control in parents and adolescents using best-worst scaling. Respir Med. 2014 Jun;108(6):842-51. doi: 10.1016/j.rmed.2014.03.014. Epub 2014 Apr 15. PMID: 24780719.
Sweeney K, Grubisic M, Marra CA, Kendall R, Li LC, Lynd LD. Comparison of HRQL between unicompartmental knee arthroplasty and total knee arthroplasty for the treatment of osteoarthritis. J Arthroplasty. 2013 Oct;28(9 Suppl):187-90. doi: 10.1016/j.arth.2013.05.009. Epub 2013 Jul 11. PMID: 23850408.
Bedouch P, Sadatsafavi M, Marra CA, FitzGerald JM, Lynd LD. Trends in asthma-related direct medical costs from 2002 to 2007 in British Columbia, Canada: a population based-cohort study. PLoS One. 2012;7(12):e50949. doi: 10.1371/journal.pone.0050949. Epub 2012 Dec 5. Erratum in: PLoS One. 2013;8(6). doi:10.1371/annotation/a3275f00-6d75-4430-a0d6-5b4397ba501a. PMID: 23227222; PMCID: PMC3515523.
"Centennial Alumni of Influence Award." Lynd LD. University of Saskatchewan College of Pharmacy and Nutrition. 2014.
"PharmD Teaching Award." Lynd LD. UBC Faculty of Pharmaceutical Sciences. 2013.
"Early Career Scholar." Lynd LD. Peter Wall Institute for Advanced Studies. 2011.
"New Investigator Award." Lynd LD. Canadian Institutes of Health Research. 2006.
"Career Scholar Award." Lynd LD. Michael Smith Foundation for Health Research. 2005.
"Outcomes Research in Community Pharmacy Practice: Innovation Using eHealth." Lynd LD (Co-PI). $38,463. Canadian Foundation for Innovation. 2014.
"Informing Future Orphan Drug Coverage with Scenario Studies (iFOCUSS)." Lynd LD (Co-PI), Clifford T (Co-PI), Douglas C. $235,801. CIHR-MSFHR Partnerships for Health System Improvement. 2014–2016.
"Developing a Canadian Framework for Evaluation and Decision-Making for Expensive Drugs for Rare Diseases Through Innovation, Value, and Priority Setting." Lynd LD (PI), Bryan S, Clarke L, Clifford T, Coyle D, Friedman J, Joly Y, Jones B, Klein P, Knoppers B, Lun E, Marra C, Miller F, Mitton C, Nakagawa R, Ozdemir V, Sirrs S. $1.47M. CIHR. 2012–2017.
"Platform for Outcomes Research and Translation in Asthma and Allergy (PORTAL) – Renewal." Lynd LD (PI), Unger W, Marra C, Dell S, Elliott S, Clarke A, FitzGerald JM. $150,000. AllerGen NCE. 2012–2016.
"Evaluation of Pharmacy Adaptation Services in British Columbia." Lynd LD (Co-PI), Marra CA (Co-PI), Grindrod K. $291,954. BC Pharmacy Association. 2009.
"Can we move from sick-care to health-care?" Lynd LD. LSI Public Talks, Personalized Medicine: Your Life, Your Genes, Your Health and Happiness. Vancouver, BC. February 4, 2015.
"Evaluating the implications of orphan drugs and rare diseases in Canada – a reimbursement/health care sustainability perspective." Lynd LD. UBC Faculty of Pharmaceutical Sciences Seminar Series. Vancouver, BC. October 8, 2014.
"Providing professional pharmacy services in British Columbia – implementation, evaluation, and reimbursement." Lynd LD. The 15th Annual Congress of the Soceity Francaise de Pharmacie Clinique (SFPC). Grenoble, FR. February 7, 2014.
"Using state choice methods in health services research and evaluation." Lynd LD. Universitè Joseph Fournier. February 5, 2014. Grenoble, FR. February 5, 2014. "Personalized medicine, orphan disease drugs, and the future of health economics." Lynd LD. Panelist and Speaker. The 9th World Congress on Health Economics. Sydney, AU. July 10, 2013.
Dr. Larry Lynd received his BSP in 1986 from the University of Saskatchewan and his PhD in the Department of Health Care and Epidemiology at UBC in 2002. He then completed a two-year post-doctoral fellowship in health economics with Dr. Bernie O'Brien at McMaster University. Currently, Dr. Lynd is associate dean, research; professor and director of the Collaboration for Outcomes Research and Evaluation (CORE) at the UBC Faculty of Pharmaceutical Sciences; scientist at the Centre for Clinical Epidemiology and Evaluation; scientist at the Centre for Health Evaluation and Outcomes Sciences; scholar at the Peter Wall Institute of Advanced Studies; and associate of the UBC School of Population and Public Health.
Dr. Lynd has made significant contributions serving on a number of committees, including chair of the Health Canada Special Advisory Committee on Non-Prescription Drugs, Special Advisory Committee to the Respiratory and Allergy Therapies Division of Health Canada, BC Ministry of Health Services Expensive Drugs for Rare Diseases Committee, and the BC PharmaNet Data Stewardship Committee.
Dr. Lynd conducts state of the art outcomes research and epidemiologic studies including cost-effectiveness analysis and therapeutic risk benefit analysis. Through his involvement in the BC Ministry of Health Expensive Drug for Rare Diseases Committee, to which he was appointed for a second term for his health economics expertise, he has identified significant knowledge gaps relating to policy and decision-making associated with orphan drugs and personalized medicine. As such, he was successful in receiving a Canadian Institutes of Health Research team grant as the principal investigator for a national, multi-disciplinary team of economists, epidemiologists, policy researchers, ethicists, lawyers, clinicians, and knowledge users to develop new knowledge relating to funding and reimbursement of expensive drugs for rare diseases.
One of Dr. Lynd's primary areas of interest is in respiratory diseases, specifically asthma and chronic obstructive pulmonary disease. Because the evaluation of health outcomes has no geographic or disease-specific boundaries, he is also involved in a number of international studies that have the potential to influence policy in countries such as Rwanda and Cambodia. Overall, the ultimate research goal for Dr. Lynd is the translation of knowledge into improved patient outcomes and the health care decision-making process.